Eagle Pharmaceuticals (EGRX) Tops Q2 EPS by 15c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Eagle Pharmaceuticals, Inc. Reports Second Quarter 2018 Results
August 7, 2018 6:50 AM EDT-- Q2 2018 net income was $0.18 per basic and $0.17 per diluted share and adjusted non-GAAP net income of $0.99 per basic and $0.95 per diluted share --
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)-- Eagle Pharmaceuticals, Inc. (Eagle or the Company) (Nasdaq: EGRX) today announced its financial results for the three and six months ended June 30, 2018. Highlights of and subsequent to the second quarter of 2018 include:
Business and Recent Highlights:
EHS clinical trial for RYANODEX® will be conducted August 20 24, 2018 during the Hajj pilgrimage;... More